japan
formid
tradit
immunolog
research
start
shibasaburo
kitasato
return
japan
studi
robert
koch
went
build
almost
singlehandedli
research
tradit
investig
medic
research
engag
fight
infecti
diseas
past
decad
japanes
immunologist
involv
mani
import
discoveri
forefront
immunolog
research
yet
come
translat
new
discoveri
clinic
innov
new
therapi
japan
track
record
seem
modest
despit
tremend
output
high
visibl
basic
immunolog
research
japan
today
come
translat
basic
scienc
new
therapi
pharmaceut
product
japanes
immunologist
hardli
leader
even
though
new
approach
evidencebas
medicin
translat
research
also
arriv
japan
recent
studi
indic
wherea
research
output
biomed
scienc
japan
increas
consider
past
two
decad
true
mani
clinic
field
exampl
literatur
studi
find
evid
one
random
control
trial
field
infecti
diseas
japan
ref
although
might
underst
realiti
true
proport
casecontrol
cohort
studi
japan
inde
smaller
countri
problem
breakthrough
discoveri
basic
research
easili
translat
new
therapi
hardli
limit
japan
field
immunolog
howev
true
case
immunolog
societi
demand
mount
develop
countri
increas
resist
antibiot
emerg
sever
acut
respiratori
syndrom
sar
west
nile
viru
remind
erad
infecti
diseas
unlik
occur
time
preval
allergi
rise
rapidli
mani
industri
countri
least
unit
state
terrorist
threat
led
increas
spend
biodef
research
good
deal
flow
field
immunolog
japan
research
centr
allergi
immunolog
rcai
translat
research
immunolog
japanes
perspect
conservat
mhlw
benefit
one
major
client
ministri
japanes
medic
associ
jma
japan
cooper
regulatori
system
regulatori
decis
make
highli
depend
relationship
ministri
client
industri
gener
public
health
ministri
jmaa
power
lobbi
group
tight
connect
rule
liber
democrat
parti
ldp
remain
perhap
import
client
jma
repeatedli
taken
posit
separ
medic
therapi
medic
research
kind
activ
carri
eventu
goal
help
patient
label
medic
rather
research
jma
also
taken
increasingli
aggress
stanc
toward
privaci
protect
medic
research
one
practic
implic
although
focu
rcai
basic
research
polit
patron
also
bestow
practic
mission
centr
contribut
activ
develop
new
therapi
common
allerg
condit
japanes
cedar
pollen
allergi
sens
rcai
exemplari
case
two
decad
unpreced
growth
research
fund
life
scienc
today
scientist
japan
increasingli
ask
deliv
research
result
social
relev
time
seem
ripe
initi
debat
better
link
biolog
research
clinic
applic
reason
continu
lack
integr
basic
scienc
clinic
pharmaceut
applic
japanes
medic
research
especi
immunolog
argu
lack
cooper
scientist
work
basic
research
clinician
larg
result
reaction
given
set
incent
circumst
rather
consciou
choic
scientist
work
toward
professorship
research
career
larg
nation
univers
real
incent
engag
translat
research
wherea
clinician
engag
clinic
research
cut
edg
scienc
typic
mean
littl
inflat
risk
without
much
prospect
addit
merit
yet
next
year
engag
aggress
translat
research
could
turn
crucial
basic
immunologist
japan
maintain
fund
perhap
also
research
product
floyd
e
bloom
argu
year
presidenti
address
annual
meet
american
associ
advanc
scienc
unit
state
healthcar
system
seem
illprepar
reap
benefit
present
advanc
biolog
research
true
respect
japan
former
health
ministri
offici
observ
compar
studi
medic
research
polici
publish
earli
healthcar
polici
japan
never
integr
scienc
polici
despit
number
chang
numer
report
polici
document
remain
true
today
sever
reason
fact
first
research
high
agenda
ministri
health
labour
welfar
mhlw
also
manag
japan
nation
health
insur
pension
system
two
largest
budget
item
govern
mhlw
also
regul
drug
approv
decid
prize
new
pharmaceut
howev
research
best
minor
occup
ministri
fact
numer
case
health
ministri
offici
activ
oppos
aggress
move
ministri
support
innov
medic
scienc
technolog
inher
conservat
mhlw
without
reason
although
much
critic
japan
healthcar
system
qualiti
medic
treatment
japan
provid
citizen
univers
access
healthcar
boast
one
lowest
child
mortal
rate
perhap
highest
life
expect
industri
countri
although
rise
healthcar
cost
japan
much
issu
debat
elsewher
remain
fact
bare
gross
domest
product
gdp
japan
spend
much
less
healthcar
organ
econom
cooper
develop
oecd
countri
less
spend
clinic
research
rcai
face
challeng
organiz
issu
exampl
branch
japan
foremost
basic
scienc
research
institut
centr
direct
access
intern
hospit
facil
depend
collabor
adjac
hospit
tokyo
get
access
human
materi
patient
clinic
studi
mani
way
issu
centr
face
indic
present
state
immunolog
research
japan
given
promin
centr
solut
like
broad
repercuss
wwwnaturecomreviewsimmunol
p
e
r
p
e
c
v
e
research
mani
year
discourag
work
industri
scientist
concern
observ
rule
fact
sever
case
promin
scientist
includ
former
chairman
japanes
societi
biochemistri
arrest
illeg
transfer
research
money
result
compani
public
univers
sever
legal
bill
pass
past
year
provid
universitybas
scientist
consider
freedom
attempt
fundament
rework
technolog
transfer
activ
public
sector
research
organ
japan
accord
data
publish
ministri
economi
trade
industri
meti
number
new
compani
creat
japanes
univers
professor
surg
past
year
implement
new
legisl
still
number
remain
modest
unclear
whether
japanes
industri
chang
approach
work
academia
conservat
reluct
invest
new
area
research
widespread
japanes
scientist
work
area
high
commerci
interest
transplant
immunobiolog
inquiri
biotechnolog
firm
unit
state
typic
outnumb
domest
pharmaceut
compani
compani
tend
build
link
academ
institut
small
alloc
money
form
scholarship
grant
academ
institut
overal
amount
payment
small
rather
contractu
relationship
signifi
littl
els
mutual
good
implic
compani
financ
work
privileg
access
intellectu
properti
one
promin
recent
case
former
presid
osaka
univers
tadamitsu
kishimoto
announc
return
laboratori
bench
affili
laboratori
osaka
univers
sponsor
grant
three
million
us
dollar
pharmaceut
compani
interestingli
studi
industryacademia
relat
japan
cover
field
scienc
found
growth
public
coauthor
scientist
academia
industri
japan
compar
industri
countri
includ
unit
state
although
data
interpret
care
might
collabor
research
go
industri
academia
would
admit
yet
indic
littl
actual
content
research
real
amount
transfer
knowledg
academia
industri
despit
recent
chang
ministri
put
money
research
group
rather
individu
project
simpl
way
distribut
fund
effect
without
major
administr
cost
yet
one
believ
inform
review
competit
research
programm
undertaken
member
council
scienc
technolog
polici
cstp
hardli
effici
system
success
research
group
foster
collabor
seem
limit
surprisingli
case
ministri
actual
specifi
project
need
address
link
basic
research
clinic
evalu
highli
hierarch
structur
still
preval
medic
research
case
imped
innov
research
although
ministri
notabl
ministri
educ
japan
largest
support
scientif
research
also
provid
import
fund
biomed
research
fund
clinic
research
remain
larg
domain
mhlw
lack
coordin
two
agenc
mean
followup
studi
research
fund
ministri
educ
aim
translat
research
activ
rare
gener
transfer
knowledg
new
discoveri
academia
industrytechnolog
transfer
area
japan
excel
fact
one
world
sophist
economi
academ
posit
concern
research
fund
control
fund
clinic
research
typic
given
medic
practition
involv
scientist
research
fund
medic
scienc
japan
continu
come
mhlw
despit
import
role
mhlw
ministri
minor
player
research
fund
japan
especi
compar
ministri
educ
cultur
sport
scienc
technolog
mext
furthermor
research
fund
ministri
highli
fragment
except
rel
modest
research
grant
programm
account
ministri
research
develop
budget
administ
hand
offici
minist
bureau
research
fund
mhlw
typic
paid
directli
ministri
variou
offic
spent
within
ministri
research
institut
moreov
sever
competit
research
programm
administr
mhlwrelat
organ
organ
pharmaceut
safeti
research
opsr
japanes
health
scienc
foundat
jhsf
mhlw
similar
japanes
fund
agenc
lack
staff
programm
manag
research
project
usual
organ
research
group
typic
leadership
senior
academ
use
less
anim
research
anim
facil
better
shape
japan
elsewher
anyth
contrari
tend
true
yet
clear
downsid
absenc
societi
coalit
interest
group
concern
scienc
research
vololona
rabeharisoa
michel
callon
shown
interest
studi
french
muscular
dystrophi
societi
organ
patient
famili
provid
gener
fund
research
import
role
establish
first
largescal
genet
research
centr
franc
unit
state
numer
lobbi
group
urg
increas
medic
research
spend
research
chariti
foundat
unit
kingdom
account
sizeabl
portion
overal
medic
research
fund
except
research
major
concern
patient
organ
japan
japan
spend
research
foundat
tax
similar
ordinari
corpor
modest
best
practic
mean
medic
research
japan
depend
highli
either
educ
ministri
health
ministri
similarli
wherea
research
aid
immun
toler
transplant
biodef
import
instig
immunolog
research
particularli
unit
state
situat
differ
japan
aid
nonissu
one
observ
put
number
solid
organ
transplant
per
year
still
neglig
biodef
topic
agenda
immunologist
japan
also
visibl
pressur
group
medic
research
spend
littl
interest
research
polici
politician
far
effect
lobbyist
japan
chang
slowli
past
year
promin
politician
spoken
research
one
omi
koji
even
written
sever
highli
readabl
book
scienc
scienc
polici
also
rare
move
sever
year
ago
group
politician
form
allianc
support
research
common
allergi
autoimmun
diseas
provid
support
establish
new
riken
centr
certainli
allianc
scientist
politician
rare
japanes
politician
deep
understand
scienc
research
mani
scientist
start
learn
best
navig
japan
polit
bureaucrat
world
regul
technolog
transfer
reorgan
public
sector
research
japan
major
econom
newspap
refer
univers
enter
licens
busi
incent
scientist
engag
industri
hardli
chang
regulatori
agenc
bodi
unit
state
food
drug
administr
fda
recombin
dna
advisori
board
nation
institut
health
nih
constant
target
critic
industri
group
scientist
howev
violent
clash
genet
modifi
organ
europ
remind
us
regul
import
tool
build
public
confid
scienc
contrast
arcan
rule
regul
govern
technolog
transfer
practic
japan
rel
attempt
far
regul
content
research
instead
regul
biomed
research
japan
follow
rather
cautiou
path
anyth
regul
tend
favour
permiss
rather
restrict
perhap
real
except
somewhat
unusu
bill
outlaw
human
clone
eventu
introduc
scientist
would
prefer
see
revis
replac
flexibl
regul
reluct
approach
regulatori
agenc
biomed
research
without
problem
controversi
area
research
xenotransplant
health
ministri
simpli
postpon
decis
effect
deleg
institut
review
board
irb
know
univers
irb
incap
handl
complex
regulatori
decis
safeti
xenotransplant
outcom
forbidden
clinic
trial
xenotransplant
seem
highli
unlik
japan
ministri
draft
sort
safeti
guidelin
neglig
approach
bioethic
rule
backfir
introduct
principl
inform
consent
typic
exampl
intern
harmon
pharmaceut
approv
procedur
inform
consent
practic
becam
enforc
japan
effect
predict
enrol
clinic
trial
japan
declin
steadili
fact
area
regul
remain
unclear
harvest
human
cell
tissu
research
use
result
often
paralysi
rather
anyth
goe
mani
scientist
japan
incent
alter
present
situat
mix
rel
liber
regul
virtual
absenc
public
concern
goe
insid
laboratori
easi
see
exampl
anim
right
activist
attack
anim
facil
japanes
scientist
natur
review
immunolog
volum
januari
figur
frontier
immunolog
total
intern
reflect
fluoresc
microscop
system
optim
singlemolecul
studi
live
cell
built
makio
tokunaga
imag
courtesi
rikenrcai
nig
wwwnaturecomreviewsimmunol
postwar
japan
often
character
countri
sophist
approach
industri
innov
rather
countri
basic
scientif
research
held
high
esteem
case
immunobiolog
scientist
japan
shown
consider
achiev
basic
scienc
yet
effort
translat
find
therapeut
innov
seem
much
less
preval
let
alon
fruit
lead
immunologist
japan
chosen
pursu
clinic
develop
aggress
explain
sever
extern
factor
includ
organ
medic
research
academia
research
polici
research
fund
practic
clinic
environ
hostil
therapeut
innov
peculiar
technolog
transfer
regim
regulatori
uncertainti
well
lack
express
societi
demand
research
need
better
physic
infrastructur
biomed
research
oppos
biolog
medic
research
clinic
studi
also
mark
chang
japan
research
fund
regim
japanes
academ
institut
provid
scientist
right
incent
engag
clinic
translat
research
activ
fund
agenc
much
improv
situat
provid
fund
research
network
includ
molecular
biologist
clinician
design
programm
specif
target
link
basic
research
clinic
innov
sever
programm
launch
past
year
includ
research
revolut
initi
provid
fund
translat
research
area
develop
bcg
mycobacterium
bovi
bacillu
calmetteguerin
vaccin
transplant
immunobiolog
cancer
immunosurveil
still
longterm
fundament
reorgan
research
fund
creation
dedic
